Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

It's little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

I’m Kelly Grant, a health reporter with The Globe and Mail. Yesterday, the Canadian Medical Association Journal published the first new guideline on the treatment of childhood obesity in nearly 20 ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called ... expand its lineup of advanced weight-loss treatments. Although the company’s drugs have been popular, trials ...

I am concerned the mad scramble to get hold of weight-loss jabs has led to a Wild West market, where it's easy to buy these drugs, particularly online, and self-administer them without any advice.

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...